Cargando…
Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017
OBJECTIVE: To evaluate the effectiveness of two palivizumab programmes targeting high-risk infants, defined by prematurity, diagnosis of comorbidities and geography, and assess potential disparities by neighbourhood income. DESIGN: Controlled, interrupted time series. SETTING: Ontario, Canada. PATIE...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841493/ https://www.ncbi.nlm.nih.gov/pubmed/32859612 http://dx.doi.org/10.1136/archdischild-2020-319472 |
_version_ | 1783643819930025984 |
---|---|
author | Fitzpatrick, Tiffany McNally, James Dayre Stukel, Therese A Kwong, Jeffrey C Wilton, Andrew S Fisman, David Guttmann, Astrid |
author_facet | Fitzpatrick, Tiffany McNally, James Dayre Stukel, Therese A Kwong, Jeffrey C Wilton, Andrew S Fisman, David Guttmann, Astrid |
author_sort | Fitzpatrick, Tiffany |
collection | PubMed |
description | OBJECTIVE: To evaluate the effectiveness of two palivizumab programmes targeting high-risk infants, defined by prematurity, diagnosis of comorbidities and geography, and assess potential disparities by neighbourhood income. DESIGN: Controlled, interrupted time series. SETTING: Ontario, Canada. PATIENTS: We used linked health and demographic administrative databases to identify all children born in hospitals 1 January 1993 through 31 December 2016. Follow-up ended at the earliest of second birthday or 30 June 2017. INTERVENTION: Palivizumab-eligibility: child was born very preterm and ≤6 months old during respiratory syncytial virus (RSV) season; <24 months old with significant chronic lung or congenital heart disease; or ≤6 months, born preterm or residents of remote regions. MAIN OUTCOME: Severe RSV-related illness, defined as hospitalisation or death with a diagnosis of bronchiolitis, RSV pneumonia or RSV. RESULTS: 3 million births and 87 000 RSV-related events were identified. Over the study period, rates of severe RSV-related illness declined 65.4% among the highest risk group, eligible infants <6 months (230.6 to 79.8 admissions per 1000 child-years). Relative to changes among ineligible infants <6 months, rates dropped 10.4% (95% CI −18.6% to 39.4%) among eligible infants immediately following introduction of a national palivizumab programme in 1998. Initially, rates were considerably higher among infants from low-income neighbourhoods, but income-specific rates converged over time among eligible infants <6 months; such convergence was not seen among other children. CONCLUSIONS: Incidence of severe RSV-related illness declined over the study period. While we cannot attribute causality, the timing and magnitude of these declines suggest impact of palivizumab in reducing RSV burden and diminishing social inequities among palivizumab-eligible infants. |
format | Online Article Text |
id | pubmed-7841493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-78414932021-02-04 Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 Fitzpatrick, Tiffany McNally, James Dayre Stukel, Therese A Kwong, Jeffrey C Wilton, Andrew S Fisman, David Guttmann, Astrid Arch Dis Child Original Research OBJECTIVE: To evaluate the effectiveness of two palivizumab programmes targeting high-risk infants, defined by prematurity, diagnosis of comorbidities and geography, and assess potential disparities by neighbourhood income. DESIGN: Controlled, interrupted time series. SETTING: Ontario, Canada. PATIENTS: We used linked health and demographic administrative databases to identify all children born in hospitals 1 January 1993 through 31 December 2016. Follow-up ended at the earliest of second birthday or 30 June 2017. INTERVENTION: Palivizumab-eligibility: child was born very preterm and ≤6 months old during respiratory syncytial virus (RSV) season; <24 months old with significant chronic lung or congenital heart disease; or ≤6 months, born preterm or residents of remote regions. MAIN OUTCOME: Severe RSV-related illness, defined as hospitalisation or death with a diagnosis of bronchiolitis, RSV pneumonia or RSV. RESULTS: 3 million births and 87 000 RSV-related events were identified. Over the study period, rates of severe RSV-related illness declined 65.4% among the highest risk group, eligible infants <6 months (230.6 to 79.8 admissions per 1000 child-years). Relative to changes among ineligible infants <6 months, rates dropped 10.4% (95% CI −18.6% to 39.4%) among eligible infants immediately following introduction of a national palivizumab programme in 1998. Initially, rates were considerably higher among infants from low-income neighbourhoods, but income-specific rates converged over time among eligible infants <6 months; such convergence was not seen among other children. CONCLUSIONS: Incidence of severe RSV-related illness declined over the study period. While we cannot attribute causality, the timing and magnitude of these declines suggest impact of palivizumab in reducing RSV burden and diminishing social inequities among palivizumab-eligible infants. BMJ Publishing Group 2021-02 2020-08-28 /pmc/articles/PMC7841493/ /pubmed/32859612 http://dx.doi.org/10.1136/archdischild-2020-319472 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Fitzpatrick, Tiffany McNally, James Dayre Stukel, Therese A Kwong, Jeffrey C Wilton, Andrew S Fisman, David Guttmann, Astrid Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 |
title | Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 |
title_full | Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 |
title_fullStr | Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 |
title_full_unstemmed | Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 |
title_short | Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017 |
title_sort | palivizumab’s real-world effectiveness: a population-based study in ontario, canada, 1993–2017 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841493/ https://www.ncbi.nlm.nih.gov/pubmed/32859612 http://dx.doi.org/10.1136/archdischild-2020-319472 |
work_keys_str_mv | AT fitzpatricktiffany palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 AT mcnallyjamesdayre palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 AT stukeltheresea palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 AT kwongjeffreyc palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 AT wiltonandrews palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 AT fismandavid palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 AT guttmannastrid palivizumabsrealworldeffectivenessapopulationbasedstudyinontariocanada19932017 |